Melanoma reactive TCR-modified T cells generated without activation retain a less differentiated phenotype and mediate a superior in vivo response

Adoptive T cell therapy with T cell receptor (TCR)-modified T cells has shown promise in treating metastatic melanoma and other malignancies. However, studies are needed to improve the efficacy and durability of responses of TCR-modified T cells. Standard protocols for generating TCR-modified T cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Siao-Yi, Moore, Tamson V., Dalheim, Annika V., Scurti, Gina M., Nishimura, Michael I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233420/
https://www.ncbi.nlm.nih.gov/pubmed/34172810
http://dx.doi.org/10.1038/s41598-021-92808-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233420/
https://www.ncbi.nlm.nih.gov/pubmed/34172810
http://dx.doi.org/10.1038/s41598-021-92808-6

Ejemplares similares